CR20160333A - Proteinas de fusión de interleucina-2 y usos de las mismas - Google Patents
Proteinas de fusión de interleucina-2 y usos de las mismasInfo
- Publication number
- CR20160333A CR20160333A CR20160333A CR20160333A CR20160333A CR 20160333 A CR20160333 A CR 20160333A CR 20160333 A CR20160333 A CR 20160333A CR 20160333 A CR20160333 A CR 20160333A CR 20160333 A CR20160333 A CR 20160333A
- Authority
- CR
- Costa Rica
- Prior art keywords
- fusion proteins
- relates
- interleucine
- same
- treatment
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 5
- 108020001507 fusion proteins Proteins 0.000 title abstract 5
- 102000000588 Interleukin-2 Human genes 0.000 abstract 3
- 108010002350 Interleukin-2 Proteins 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere generalmente a proteínas de fusión de inmunoglobulinas e interleucina-2 (IL-2). Más particularmente, la invención se refiere a proteínas de fusión de inmunoglobulinas e IL-2 mutante que muestra propiedades mejoradas para su uso como agentes terapéuticos, por ejemplo, en el tratamiento de enfermedades autoinmunes y enfermedades inflamatorias mediadas por el sistema inmune. Además, la presente invención se refiere a polinucleótidos que codifican dichas proteínas de fusión, y a vectores y células hospedadoras que comprenden dichos polinucleótidos. La invención se refiere además a métodos para producir las proteínas de fusión de la invención, y a métodos de uso en el tratamiento de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461936564P | 2014-02-06 | 2014-02-06 | |
PCT/EP2015/052312 WO2015118016A1 (en) | 2014-02-06 | 2015-02-04 | Interleukin-2 fusion proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20160333A true CR20160333A (es) | 2016-09-05 |
Family
ID=52669578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20160333A CR20160333A (es) | 2014-02-06 | 2015-02-04 | Proteinas de fusión de interleucina-2 y usos de las mismas |
Country Status (32)
Country | Link |
---|---|
US (1) | US11098099B2 (es) |
EP (2) | EP3508496A1 (es) |
JP (2) | JP6306201B2 (es) |
KR (2) | KR102042246B1 (es) |
CN (2) | CN111423513A (es) |
AR (1) | AR099289A1 (es) |
AU (2) | AU2015215001B2 (es) |
BR (1) | BR112016018288A2 (es) |
CA (1) | CA2931114A1 (es) |
CL (1) | CL2016001968A1 (es) |
CR (1) | CR20160333A (es) |
DK (1) | DK3102595T3 (es) |
EA (2) | EA201992609A1 (es) |
ES (1) | ES2704731T3 (es) |
HR (1) | HRP20190028T1 (es) |
HU (1) | HUE041530T2 (es) |
IL (1) | IL245484B (es) |
LT (1) | LT3102595T (es) |
MA (1) | MA39250B1 (es) |
MX (2) | MX370283B (es) |
NZ (2) | NZ760289A (es) |
PE (1) | PE20161324A1 (es) |
PH (1) | PH12016501406A1 (es) |
PL (1) | PL3102595T3 (es) |
PT (1) | PT3102595T (es) |
RS (1) | RS58149B1 (es) |
SG (1) | SG11201606369XA (es) |
SI (1) | SI3102595T1 (es) |
TW (1) | TWI671318B (es) |
UA (1) | UA120847C2 (es) |
WO (1) | WO2015118016A1 (es) |
ZA (1) | ZA201603262B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
MX370283B (es) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas. |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
HUE043038T2 (hu) | 2014-08-11 | 2019-07-29 | Delinia Inc | Regulator T-sejteket szelektíven aktiváló, módosított IL-2-változatok autoimmun betegségek kezelésére |
US10285948B2 (en) | 2014-12-05 | 2019-05-14 | Janssen Pharmaceutica Nv | Anticancer compositions |
CA3006477A1 (en) | 2015-12-04 | 2017-06-08 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
CA3011331A1 (en) | 2016-01-14 | 2017-07-20 | Intrexon Actobiotics N.V. | Compositions and methods for the treatment of type 1 diabetes |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
CA3038679A1 (en) | 2016-09-28 | 2018-04-05 | Xoma (Us) Llc | Antibodies that bind interleukin-2 and uses thereof |
WO2018073365A1 (en) | 2016-10-19 | 2018-04-26 | F. Hoffmann-La Roche Ag | Method for producing an immunoconjugate |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
EA201991142A1 (ru) * | 2016-11-08 | 2019-10-31 | Варианты il-2 для лечения аутоиммунных заболеваний | |
AU2017378308A1 (en) * | 2016-12-13 | 2019-06-20 | Delinia, Inc. | Multivalent regulatory T cell modulators |
WO2018170288A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
BR112019024127A2 (pt) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | Imunotolerância alvejada |
JOP20190271A1 (ar) * | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
CN111615396A (zh) * | 2017-11-21 | 2020-09-01 | 小利兰·斯坦福大学董事会 | 白介素-2的部分激动剂 |
CA3084262A1 (en) * | 2017-12-06 | 2019-06-13 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered proteins to enhance sensitivity of a cell to il-2 |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
WO2019125732A1 (en) * | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
EP3752178A1 (en) | 2018-02-16 | 2020-12-23 | Iltoo Pharma | Use of interleukin 2 for treating sjögren's syndrome |
EA202092316A1 (ru) | 2018-03-28 | 2021-05-25 | Бристол-Маерс Сквибб Компани | Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения |
WO2020007937A1 (en) | 2018-07-03 | 2020-01-09 | Iltoo Pharma | Use of interleukin-2 for treating systemic sclerosis |
AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
CA3125529A1 (en) * | 2019-01-07 | 2020-07-16 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
CN111944036A (zh) * | 2019-05-14 | 2020-11-17 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
KR20220035333A (ko) | 2019-05-20 | 2022-03-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Madcam 표적 면역관용 |
WO2020252421A2 (en) * | 2019-06-14 | 2020-12-17 | Cugene, Inc. | Novel interleukin-2 variants and bifunctional fusion molecules thereof |
CA3146156A1 (en) * | 2019-07-12 | 2021-01-21 | Proviva Therapeutics (Hong Kong) Limited | Il-2 compositions and methods of use thereof |
CN115315436A (zh) | 2020-01-10 | 2022-11-08 | 明峰治疗股份公司 | 修饰的il-2多肽及其用途 |
CA3166509A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Biased il2 muteins methods and compositions |
IL295143A (en) | 2020-02-13 | 2022-09-01 | Hoffmann La Roche | A method for determining the loading state of aav particles using nuclear magnetic resonance relaxometry |
JP2023518443A (ja) * | 2020-03-19 | 2023-05-01 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | インターロイキン2変異体およびその使用 |
JP2023526282A (ja) | 2020-05-13 | 2023-06-21 | ボナム セラピューティクス,インク. | タンパク質複合体の組成物及びその使用方法 |
CN113912735A (zh) * | 2020-07-08 | 2022-01-11 | 南京师范大学 | 多肽二聚体及其用途 |
JP2023548311A (ja) | 2020-10-29 | 2023-11-16 | ブリストル-マイヤーズ スクイブ カンパニー | 疾患の治療のための融合タンパク質 |
CN112724259B (zh) * | 2020-11-16 | 2022-12-20 | 天津林达生物科技有限公司 | 人血清白蛋白与白介素2的融合蛋白及其用途 |
CN116635403A (zh) * | 2020-12-04 | 2023-08-22 | 豪夫迈·罗氏有限公司 | pH依赖性突变型白细胞介素-2多肽 |
WO2022179970A1 (en) | 2021-02-24 | 2022-09-01 | F. Hoffmann-La Roche Ag | Regeneration and multiple use of depth filters |
WO2023057588A1 (en) * | 2021-10-06 | 2023-04-13 | Iltoo Pharma | Interleukin 2 chimeric constructs with targeting specificy to inflamed tissues |
GB202115122D0 (en) * | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
WO2024056154A1 (en) | 2022-09-12 | 2024-03-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Interleukin-2 for use in treating autism spectrum disorder |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
CN116554356B (zh) * | 2023-05-16 | 2024-01-23 | 武汉大学 | 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2388385B1 (fr) | 1977-04-18 | 1982-01-08 | Hitachi Metals Ltd | Piece d'ornement fixee par des aimants permanents |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5650150A (en) | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
JP2002505086A (ja) | 1998-02-25 | 2002-02-19 | レキシジェン ファーマシューティカルズ コーポレイション | 抗体ベースの融合タンパク質の循環半減期の増強 |
US6955807B1 (en) * | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
ES2381025T3 (es) * | 2001-12-04 | 2012-05-22 | Merck Patent Gmbh | Inmunocitocinas con selectividad modulada |
US7432063B2 (en) | 2002-02-14 | 2008-10-07 | Kalobios Pharmaceuticals, Inc. | Methods for affinity maturation |
WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
JP2007527242A (ja) * | 2004-03-05 | 2007-09-27 | カイロン コーポレーション | 治療剤の患者耐容性を予測するためのインビトロ試験システム |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
CA2885854C (en) | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ox40l抗體 |
US20060110398A1 (en) | 2004-11-24 | 2006-05-25 | Schering Corporation | DAP-10 and uses thereof |
JP2009542592A (ja) | 2006-07-06 | 2009-12-03 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2媒介性免疫応答の有効性を高める組成物および方法 |
JP2010534469A (ja) | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Kdr指向性標的化結合物質およびその使用 |
US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
CN101970730A (zh) | 2007-12-19 | 2011-02-09 | 森托科尔奥索生物科技公司 | 通过融合到pⅨ或pⅦ来设计和生成人从头pⅨ噬菌体展示文库,载体、抗体及方法 |
DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
JP5766124B2 (ja) | 2009-01-21 | 2015-08-19 | アムジェン インコーポレイテッド | 炎症性疾患および自己免疫疾患の処置の組成物および方法 |
SG187746A1 (en) | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
CU23923B1 (es) | 2010-11-12 | 2013-07-31 | Ct De Inmunología Molecular | Polipéptidos derivados de la il-2 con actividad agonista |
PE20140303A1 (es) | 2011-02-10 | 2014-03-22 | Roche Glycart Ag | Polipeptidos interleuquina-2 mutantes |
CN103732241A (zh) | 2011-03-11 | 2014-04-16 | 公共事业救济局-巴黎医院 | 低剂量il-2用于治疗自身免疫相关病症或炎性病症的应用 |
PT2691417T (pt) * | 2011-03-29 | 2018-10-31 | Roche Glycart Ag | Variantes de fc de anticorpos |
EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
EP3626739A1 (en) * | 2011-06-24 | 2020-03-25 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
MX370283B (es) | 2014-02-06 | 2019-12-09 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas. |
MA40721A (fr) | 2014-08-06 | 2017-06-13 | The Univ Of Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
-
2015
- 2015-02-04 MX MX2016009687A patent/MX370283B/es active IP Right Grant
- 2015-02-04 RS RS20190003A patent/RS58149B1/sr unknown
- 2015-02-04 UA UAA201609263A patent/UA120847C2/uk unknown
- 2015-02-04 CN CN202010081233.4A patent/CN111423513A/zh active Pending
- 2015-02-04 LT LTEP15709419.4T patent/LT3102595T/lt unknown
- 2015-02-04 KR KR1020167021255A patent/KR102042246B1/ko active IP Right Grant
- 2015-02-04 BR BR112016018288A patent/BR112016018288A2/pt not_active Application Discontinuation
- 2015-02-04 CN CN201580007400.8A patent/CN105980410B/zh active Active
- 2015-02-04 SI SI201530545T patent/SI3102595T1/sl unknown
- 2015-02-04 CA CA2931114A patent/CA2931114A1/en active Pending
- 2015-02-04 DK DK15709419.4T patent/DK3102595T3/en active
- 2015-02-04 PT PT15709419T patent/PT3102595T/pt unknown
- 2015-02-04 SG SG11201606369XA patent/SG11201606369XA/en unknown
- 2015-02-04 ES ES15709419T patent/ES2704731T3/es active Active
- 2015-02-04 EA EA201992609A patent/EA201992609A1/ru unknown
- 2015-02-04 CR CR20160333A patent/CR20160333A/es unknown
- 2015-02-04 NZ NZ760289A patent/NZ760289A/en unknown
- 2015-02-04 EP EP18201416.7A patent/EP3508496A1/en not_active Withdrawn
- 2015-02-04 MA MA39250A patent/MA39250B1/fr unknown
- 2015-02-04 PE PE2016001255A patent/PE20161324A1/es unknown
- 2015-02-04 EA EA201691576A patent/EA034350B1/ru not_active IP Right Cessation
- 2015-02-04 KR KR1020197032546A patent/KR20190126205A/ko not_active Application Discontinuation
- 2015-02-04 JP JP2016550531A patent/JP6306201B2/ja active Active
- 2015-02-04 NZ NZ719654A patent/NZ719654A/en unknown
- 2015-02-04 EP EP15709419.4A patent/EP3102595B1/en active Active
- 2015-02-04 AU AU2015215001A patent/AU2015215001B2/en active Active
- 2015-02-04 HU HUE15709419A patent/HUE041530T2/hu unknown
- 2015-02-04 PL PL15709419T patent/PL3102595T3/pl unknown
- 2015-02-04 WO PCT/EP2015/052312 patent/WO2015118016A1/en active Application Filing
- 2015-02-04 US US14/613,831 patent/US11098099B2/en active Active
- 2015-02-05 AR ARP150100325A patent/AR099289A1/es unknown
- 2015-02-05 TW TW104103962A patent/TWI671318B/zh active
-
2016
- 2016-05-04 IL IL24548416A patent/IL245484B/en active IP Right Grant
- 2016-05-13 ZA ZA201603262A patent/ZA201603262B/en unknown
- 2016-07-15 PH PH12016501406A patent/PH12016501406A1/en unknown
- 2016-07-26 MX MX2019014695A patent/MX2019014695A/es unknown
- 2016-08-04 CL CL2016001968A patent/CL2016001968A1/es unknown
-
2018
- 2018-03-07 JP JP2018040501A patent/JP2018102312A/ja active Pending
-
2019
- 2019-01-03 HR HRP20190028TT patent/HRP20190028T1/hr unknown
- 2019-11-13 AU AU2019264579A patent/AU2019264579A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20160333A (es) | Proteinas de fusión de interleucina-2 y usos de las mismas | |
PE20150752A1 (es) | Proteinas de fusion de interleuquina-2 y usos de las mismas | |
CO2018002450A2 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
UY36021A (es) | Proteìnas fc multimèricas | |
PE20150645A1 (es) | Proteinas de fusion de interleuquina 10 y usos de las mismas | |
BR112017018975A2 (pt) | proteínas de fusão compreendendo uma proteína de ligação e um polipeptídeo de interleucina-15 tendo uma afinidade reduzida com il15ra e usos terapêuticos das mesmas | |
CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
EA202190903A2 (ru) | Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний | |
BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
CL2016001579A1 (es) | Nuevas indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen, así como su uso para la preparación de medicamentos. | |
BR112017007003A2 (pt) | método para modulação de atividade de células imunes induzidas por car | |
CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CL2019001043A1 (es) | Anticuerpos anti-il-33 y usos de los mismos. | |
ECSP18041733A (es) | Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación | |
BR112018014668A2 (pt) | multímeros de fc de igg recombinante | |
CL2018002769A1 (es) | Composiciones y métodos recombinantes de inmunoglobulina intravenosa (rlvig) para producción y uso. | |
PE20170088A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos | |
CR20160593A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
CR20150544A (es) | Proteinas específicas para el baff y para la b7rp1 y sus usos | |
BR112016019390A2 (pt) | proteínas de fusão uti | |
CL2019000702A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos. | |
CR20150477A (es) | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso |